Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Myles A IngramBrianna N LaurenYoanna PumpalovaJiheum ParkFrancesca LimSusan E BatesFay KastrinosGulam A ManjiChung Yin KongChin HurPublished in: Cancer reports (Hoboken, N.J.) (2022)
Our modeling analysis suggests that FOLFIRNOX is the cost-effective treatment compared to G-nP for BR/LA PDAC despite having a higher cost of total care due to TRAE costs. Trial data with sufficient follow-up are needed to confirm our findings.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- phase ii study
- palliative care
- clinical trial
- study protocol
- electronic health record
- phase iii
- quality improvement
- phase ii
- combination therapy
- lymph node
- affordable care act
- data analysis
- smoking cessation
- double blind